Year: 2019

Með samþykkt laga 137/2019 um Húsnæðis- og mannvirkjastofnun og laga um úrvinnslu eigna og skulda ÍL-sjóðs (sem samþykkt var á Alþingi 17. desember 2019, sjá nánar þingskjal 381/2019) er staðfest breyting á starfsemi ÍL-sjóðs (áður Íbúðalánasjóðs) þannig að sjóðurinn verði ekki lengur virk fjármálastofnun, veiti ekki ný lán og gefi ekki út frekari markaðsskuldabréf. Forræði ÍL-sjóðs og ábyrgð á úrvinnslu eigna og skulda sjóðsins, flyst frá og með 31. desember 2019 til fjármála- og efnahagsráðuneytisins....

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Dec. 30, 2019 (GLOBE NEWSWIRE) — Balmoral Resources Ltd. (TSX:BAR) (“Balmoral” or the “Company“) announces that it has closed the previously announced (see news release NR19-28, dated December 16, 2019) non-brokered flow-through private placement (the “Offering”).Pursuant to the closing of the Offering the Company issued 8,930,000 Quebec flow-through common shares (“Quebec FT Shares”) at a price of $0.51 per Quebec FT Share for gross proceeds of $4,554,300.  The Quebec FT Shares issued will be subject to a four month and one day hold period from the date of closing of the Offering under applicable securities laws in Canada. The net proceeds...

ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) — The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions.As previously announced, Gemphire’s stockholders voted to approve the proposals required to complete the merger transaction. In connection with these approvals, the Board of Directors of Gemphire has approved a reverse stock split of Gemphire’s common stock at a ratio of one new share for every 25 shares outstanding, which is expected to become effective immediately prior to the consummation of the merger. Immediately following the closing, the combined company will be renamed “NeuroBo Pharmaceuticals, Inc.”,...

16:00 London, 18:00 Helsinki, 30 December 2019 – Afarak Group Plc (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR)AFARAK GROUP PLC´S 2020 FINANCIAL REPORTING CALENDARStock Exchange ReleaseAfarak Group Plc (“Afarak” or the “Company”) will publish its financial results as follows:– Full Year 2019 Results on Friday 28 February 2020– Annual Report 2019 during the week commencing 30 March 2020– Report for six months ending 30 June on Friday 21 August 2020The Company’s Annual General Meeting is scheduled to be held on Tuesday 26 May 2020. A separate notice of General Meeting will be published prior to the meeting in 2020.Production reports will be issued quarterly.Helsinki, December 30, 2019Afarak...

16:00 Lontoo, 18:00 Helsinki, 30.12.2019 – Afarak Group Oyj (”Afarak” tai ”Yhtiö) (LSE: AFRK, NASDAQ: AFAGR)AFARAK GROUP OYJ:N TALOUDELLINEN RAPORTOINTI VUONNA 2020PörssitiedoteAfarak Group Oyj (“Afarak” tai “Yhtiö”) julkistaa tulosraporttinsa seuraavasti:– Vuoden 2019 tilinpäätöstiedote perjantaina 28.2.2020– Vuoden 2019 vuosikertomus 30. maaliskuuta 2020 alkavalla viikolla– Osavuosikatsaus tammi-kesäkuulta perjantaina 21.8.2020Varsinainen yhtiökokous on suunniteltu pidettäväksi tiistaina 26.5.2020. Varsinaiseen yhtiökokoukseen julkaistaan erillinen kutsu määräajassa vuonna 2020.Tuotantoraportit tullaan julkaisemaan neljännesvuosittain.Helsingissä, 30.12.2019Afarak Group OyjHallitusLisätietoja:Guy...

VIRGINIA BEACH, Va., Dec. 30, 2019 (GLOBE NEWSWIRE) — BRAVO MULTINATIONAL INCORPORATED (OTC:BRVO) and ELEMENT GLOBAL, INC. (OTC.ELGL) announces a “Letter of Intent,” whereas BRVO acquires ELGL’s subisidiary, ELEMENT GLOBAL MINING (EGM).The “Letter of Intent” provided for negotiations and due diligence, with an expected outcome of an acquisition of ELEMENT GLOBAL MINING (EGM). BRVO believes this acquisition should bring significant value to the Company and its shareholders.For further information about this release, contact Investor Relations, YES INTERNATIONAL, at 757-306-6090 and yes@yesinternational.com, www.elementglobal.com and www.bravomultinational.com.Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking...

Company Release no. 23/2019To: NASDAQ Copenhagen A/S                                                             Copenhagen, Denmark, 30 December 2019 Veloxis Pharmaceuticals Announces Financial Calendar for 2020 Veloxis Pharmaceuticals A/S (OMX: VELO) today announced its financial calendar for 2020. The full calendar is shown below. For more information, please contact: About Veloxis PharmaceuticalsVeloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant...

The Board of Directors of Valitor, a subsidiary of Arion Bank, has decided to undertake a reorganisation of the company in order to strengthen Valitor’s core business and to turn around the company’s losses. Cost relating to the changes is expected to be around ISK 600 million which will be reflected in Arion Bank’s Q4 financial results. The expected measures will take the company from an operating loss to an EBITDA profit.  Further details will be announced by Valitor within two weeks’ time. Valitor’s investments in international operations have been considerable in recent years. These investments have led to revenue growth, but sales of omni-channel solutions – a product line for large pan-European companies – have not met expectations. Compared to a total investment of ISK 6 billion...

Stjórn Valitor, dótturfélag Arion banka, hefur ákveðið að ráðast í endurskipulagningu á félaginu til að styrkja kjarnastarfsemi þess og snúa við taprekstri. Kostnaður við breytingarnar er áætlaður 600 milljónir króna og verður bókfærður í uppgjöri Arion banka samstæðunnar fyrir 4. ársfjórðung 2019. Gert er ráð fyrir að þessar aðgerðir Valitor breyti afkomu félagsins úr tapi yfir í rekstrarhagnað fyrir afskriftir og fjármagnsliði (e. EBITDA). Valitor mun greina nánar frá inntaki fyrirhugaðra breytinga innan tveggja vikna.Fjárfestingar Valitor í alþjóðlegri...